Provided herein are methods for the diagnosis, prognosis, or management of proliferative hematological disorders and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of leukemia patients.
展开▼